Browse the evidence

Evidence suggests a reduced incidence of several gastrointestinal cancers with GLP-1 receptor agonist use.

GLP-1 receptor agonists may be considered for patients at risk of gastrointestinal cancers.

The development of oral formulations such as oral Semaglutide is expected to provide convenience for patients and enhance their willingness to receive treatment.

Practitioners should consider the potential of oral Semaglutide to improve patient adherence to obesity treatment.

Patient factors potentially contributing to increased aspiration risks included a higher body mass index, type 2 diabetes mellitus, gastro-oesophageal reflux disease, emergency case, and time from GLP-1 agonist cessation.

Understanding these risk factors can help clinicians better assess patients on GLP-1 agonists before surgery.

Fecal transplant may have a preventive role in diabetes progression.

Consider the potential of fecal transplants in diabetes prevention strategies.

Resistance training tempo has minimal overall effect on muscle hypertrophy.

Practitioners may consider that varying resistance training tempo may not significantly impact muscle growth.

Specific warm-up (SWU) protocols are similar to no warm-up (CON) regarding resistance training (RT) performance and perceptual responses.

Practitioners may consider skipping warm-up protocols to save time without compromising performance.

The comparison of 1SET and 2SET to CON indicated negligible to small potential differences for all outcomes.

The differences in warm-up protocols may not be significant enough to warrant changes in practice.

Posterior probabilities of SWU conditions being superior to CON remained relatively low for the bench press and 45° leg press.

There is little evidence to support the necessity of specific warm-up protocols for improving performance.

GLP-1 receptor agonists (GLP-1RAs) have adverse events associated with their increased use.

Practitioners should be aware of the potential adverse events when prescribing GLP-1RAs.

Weight loss magnitude was lower in patients taking GLP-1 RAs compared to postbariatric patients (29.9 kg vs 47.2 kg).

Understanding the differences in weight loss can help tailor interventions for patients seeking body contouring.

GLP-1RAs users demonstrated significantly reduced risks of poor functional outcomes (odds ratio 0.37, 95% CI 0.21-0.66).

Using GLP-1 receptor agonists may enhance functional recovery in patients post-treatment.

GLP-1RAs users had significantly reduced risks of new subarachnoid hemorrhage (odds ratio 0.39, 95% CI 0.27-0.56).

GLP-1 receptor agonists may lower the risk of subarachnoid hemorrhage in treated patients.

GLP-1 agonists may decrease sexual desire through increased serotonergic activity at the 5-HT2C receptor.

Clinicians should consider the potential impact of GLP-1 agonists on sexual desire when prescribing these medications.

The effects of GLP-1 agonists on sexual desire may be overlooked due to competing influences.

Awareness of these competing influences is crucial for healthcare providers managing patients on GLP-1 agonists.

Systematic measurement of sexual desire should be prioritized in future research on GLP-1 agonists.

Researchers should include sexual desire as a key outcome in studies involving GLP-1 agonists.

Gastrointestinal complaints were common but did not significantly influence satisfaction ratings or decisions to continue treatment.

Practitioners should note that while gastrointestinal side effects are common, they may not deter patients from continuing treatment if weight loss is achieved.

Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Practitioners should adopt a long-term management strategy for obesity treatment.

A modified prolactin-releasing peptide, NN501, reduces body weight primarily through sustained fatty acid oxidation rather than hypophagia.

NN501 may be a viable alternative therapy for obesity management focusing on fatty acid oxidation.

NN501 causes weight loss without causing obvious aversive responses.

NN501 may provide a weight loss option without the side effects commonly associated with other treatments.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of corticosteroid use in patients with inflammatory bowel disease (IBD) compared to non-GLP-1 users.

Clinicians can consider GLP-1RAs for weight management in IBD patients without concern for increased corticosteroid use.

Up to 33% of the weight lost on GLP-1 RAs may be lean tissue mass.

Practitioners should monitor body composition changes in patients using GLP-1 RAs.

Discontinuation rates for GLP-1 RAs can be up to 80% after 2 years.

Practitioners should be aware of high discontinuation rates when prescribing GLP-1 RAs.

GLP-1RAs may raise safety concerns related to weight loss and altered glucose regulation in ALS.

Monitoring for weight loss and glucose regulation is essential when considering GLP-1RAs for ALS.

LLM responses provided appropriate information about standard GLP1RA-related queries but lacked updated information on emerging concerns.

Practitioners should be aware that while LLMs can provide useful information, they may not reflect the latest developments in GLP1RA therapy.